Now showing items 1-1 of 1
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2017)
Background: Approximately 15%–20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in ...